ADMA BIOLOGICS, INC. Selling, General and Administrative Expense
ADMA BIOLOGICS, INC. (ADMA) reported Selling, General and Administrative Expense of $26.74 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-05
- ADMA BIOLOGICS, INC. selling, general and administrative expense for the quarter ending 2026-06-30 was $26.74M, a 20.36% increase year-over-year.
- ADMA BIOLOGICS, INC. selling, general and administrative expense for the quarter ending 2026-03-31 was $26.74M, a 11.06% increase year-over-year.
- ADMA BIOLOGICS, INC. selling, general and administrative expense for the quarter ending 2025-12-31 was $23.51M, a 0.84% increase year-over-year.
- ADMA BIOLOGICS, INC. selling, general and administrative expense for the quarter ending 2025-09-30 was $21.78M, a 17.33% increase year-over-year.
- ADMA BIOLOGICS, INC. selling, general and administrative expense for fiscal 2025 was $91.58M, a 23.55% increase from fiscal 2024.
- ADMA BIOLOGICS, INC. selling, general and administrative expense for fiscal 2024 was $74.12M, a 25.59% increase from fiscal 2023.
- ADMA BIOLOGICS, INC. selling, general and administrative expense for fiscal 2023 was $59.02M, a 12.51% increase from fiscal 2022.
- ADMA BIOLOGICS, INC. selling, general and administrative expense for fiscal 2022 was $52.46M, a 22.29% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 6 month as first filed | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 9 month as first filed | Selling, General and Administrative Expense 12 month | Selling, General and Administrative Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $26.74M 10-Q · filed 2026-08-05 | $53.48M 10-Q · filed 2026-08-05 | $76.99M derived: sum of 3 quarters · filed 2026-08-05 | $98.77M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $26.74M 10-Q · filed 2026-05-06 | $50.25M derived: sum of 2 quarters · filed 2026-05-06 | $72.03M derived: sum of 3 quarters · filed 2026-05-06 | $94.24M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $23.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $45.29M derived: sum of 2 quarters · filed 2026-02-25 | $67.50M derived: sum of 3 quarters · filed 2026-08-05 | $91.58M 10-K · filed 2026-02-25 | ||||
| 2025-09-30 | $21.78M 10-Q · filed 2025-11-05 | $43.99M derived: sum of 2 quarters · filed 2026-08-05 | $68.07M 10-Q · filed 2025-11-05 | $91.39M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $22.21M 10-Q · filed 2026-08-05 | $46.29M 10-Q · filed 2026-08-05 | $69.61M derived: sum of 3 quarters · filed 2026-08-05 | $88.17M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $24.08M 10-Q · filed 2026-05-06 | $47.40M derived: sum of 2 quarters · filed 2026-05-06 | $65.96M derived: sum of 3 quarters · filed 2026-05-06 | $82.56M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $23.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $41.88M derived: sum of 2 quarters · filed 2026-02-25 | $58.48M derived: sum of 3 quarters · filed 2026-02-25 | $74.12M 10-K · filed 2026-02-25 | ||||
| 2024-09-30 | $18.56M 10-Q · filed 2025-11-05 | $35.17M derived: sum of 2 quarters · filed 2025-11-05 | $50.81M 10-Q · filed 2025-11-05 | $66.34M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-06-30 | $16.61M 10-Q · filed 2025-08-06 | $32.25M 10-Q · filed 2025-08-06 | $47.78M derived: sum of 3 quarters · filed 2026-02-25 | $62.51M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-03-31 | $15.64M 10-Q · filed 2025-05-07 | $31.17M derived: sum of 2 quarters · filed 2026-02-25 | $45.90M derived: sum of 3 quarters · filed 2026-02-25 | $60.15M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2023-12-31 | $15.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $30.26M derived: sum of 2 quarters · filed 2026-02-25 | $44.51M derived: sum of 3 quarters · filed 2026-02-25 | $59.02M 10-K · filed 2026-02-25 | ||||
| 2023-09-30 | $14.73M 10-Q · filed 2024-11-07 | $14.73M 10-Q · filed 2023-11-08 | $28.97M derived: sum of 2 quarters · filed 2024-11-07 | $43.48M 10-Q · filed 2024-11-07 | $43.49M 10-Q · filed 2023-11-08 | $57.38M derived: sum of 4 quarters · filed 2025-03-18 | ||
| 2023-06-30 | $14.25M 10-Q · filed 2024-08-08 | $14.25M 10-Q · filed 2023-08-09 | $28.76M 10-Q · filed 2024-08-08 | $28.76M 10-Q · filed 2023-08-09 | $42.65M derived: sum of 3 quarters · filed 2025-03-18 | $55.55M derived: sum of 4 quarters · filed 2025-03-18 | ||
| 2023-03-31 | $14.51M 10-Q · filed 2024-05-09 | $14.51M 10-Q · filed 2023-05-10 | $28.41M derived: sum of 2 quarters · filed 2025-03-18 | $41.30M derived: sum of 3 quarters · filed 2025-03-18 | $53.27M derived: sum of 4 quarters · filed 2025-03-18 | |||
| 2022-12-31 | $13.89M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $26.79M derived: sum of 2 quarters · filed 2025-03-18 | $38.76M derived: sum of 3 quarters · filed 2025-03-18 | $52.46M 10-K · filed 2025-03-18 | $52.46M 10-K · filed 2023-03-23 | |||
| 2022-09-30 | $12.89M 10-Q · filed 2023-11-08 | $24.86M derived: sum of 2 quarters · filed 2023-11-08 | $38.56M 10-Q · filed 2023-11-08 | $50.26M derived: sum of 4 quarters · filed 2024-02-28 | ||||
| 2022-06-30 | $11.97M 10-Q · filed 2023-08-09 | $25.67M 10-Q · filed 2023-08-09 | $37.37M derived: sum of 3 quarters · filed 2024-02-28 | $48.09M derived: sum of 4 quarters · filed 2024-02-28 | ||||
| 2022-03-31 | $13.70M 10-Q · filed 2023-05-10 | $25.40M derived: sum of 2 quarters · filed 2024-02-28 | $36.12M derived: sum of 3 quarters · filed 2024-02-28 | $46.56M derived: sum of 4 quarters · filed 2024-02-28 | ||||
| 2021-12-31 | $11.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $22.42M derived: sum of 2 quarters · filed 2024-02-28 | $32.86M derived: sum of 3 quarters · filed 2024-02-28 | $42.90M 10-K · filed 2024-02-28 | $42.90M 10-K · filed 2022-03-24 | |||
| 2021-09-30 | $10.73M 10-Q · filed 2022-11-09 | $21.16M derived: sum of 2 quarters · filed 2022-11-09 | $31.20M 10-Q · filed 2022-11-09 | $40.50M derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2021-06-30 | $10.44M 10-Q · filed 2022-08-10 | $20.47M 10-Q · filed 2022-08-10 | $29.77M derived: sum of 3 quarters · filed 2022-08-10 | $38.89M derived: sum of 4 quarters · filed 2022-08-10 | ||||
| 2021-03-31 | $10.03M 10-Q · filed 2022-05-11 | $19.33M derived: sum of 2 quarters · filed 2022-05-11 | $28.45M derived: sum of 3 quarters · filed 2022-05-11 | $37.15M derived: sum of 4 quarters · filed 2022-05-11 | ||||
| 2020-12-31 | $9.30M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $18.42M derived: sum of 2 quarters · filed 2022-03-24 | $27.12M derived: sum of 3 quarters · filed 2022-03-24 | $35.05M 10-K · filed 2022-03-24 | ||||
| 2020-09-30 | $9.12M 10-Q · filed 2021-11-10 | $17.82M derived: sum of 2 quarters · filed 2021-11-10 | $25.75M 10-Q · filed 2021-11-10 | |||||
| 2020-06-30 | $8.70M 10-Q · filed 2021-08-11 | $16.63M 10-Q · filed 2021-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |